相关实验视频
Updated: Jan 12, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
由于新型抗癌疗法治疗而产生的心脏代谢干扰
Joshua D Bennetts1, Aaron L Sverdlov2, Doan Tm Ngo1
1School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW 2308, Australia; Hunter Medical Research Institute, New Lambton Heights, Newcastle, NSW 2305, Australia; Newcastle Centre of Excellence in Cardio-Oncology, New Lambton Heights, Newcastle, NSW 2305, Australia.
现代癌症治疗方法,如免疫检查点抑制剂 (ICI) 和氨酸激酶抑制剂 (TKI),可能会导致长期的心脏和代谢问题. 早期检测和管理对于癌症幸存者来说至关重要,以防止严重的健康并发症.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
背景情况:
- 癌症疗法,包括免疫检查点抑制剂 (ICI) 和氨酸激酶抑制剂 (TKI),改善了患者的治疗结果.
- 癌症生存率的增加凸显了解决长期治疗相关并发症的必要性.
- 心脏代谢障碍是已知的,但这些疗法的副作用往往没有得到充分监测.
研究的目的:
- 审查ICI和TKI引起的心脏代谢并发症的患病率,机制和管理.
- 在当前的监测和治疗指南中发现差距.
- 倡导一种多学科的方法来管理癌症幸存者的这些毒性.
主要方法:
- 对ICI和TKI相关心脏代谢后续现有文献的系统审查.
- 综合有关流行,潜在机制和临床管理策略的证据.
- 分析当前的指导方针建议,并确定需要改进的领域.
主要成果:
- 心脏代谢并发症包括高血糖症,脂质流失症,加速动脉样硬化,甲状腺功能障碍和上腺功能不充分.
- 机制包括免疫介导的内分泌干扰,胰岛素抵抗和改变的脂质代谢.
- 目前的指导方针有限,导致这些风险的认可和管理不足.
结论:
- 与ICI和TKI相关的心脏代谢并发症对癌症幸存者构成显著的长期风险.
- 标准化的护理途径和提高认识对于早期检测和管理至关重要.
- 为了优化癌症幸存者的长期健康状况并预防癌症的发病,必须采取多学科的方法.
更多相关视频
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022
05:36Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism
Published on: February 23, 2024
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...